Intezyne is a clinical-stage bioPharmaceutical company leveraging its proprietary polymer technologies to DEVELOP BREAKTHROUGH CANCER THERAPIES.

Intezyne develops and manufactures new polymers for drug delivery applications, focusing primarily on improving the efficacy and safety of water-insoluble drugs.

Since its inception in 2004, Intezyne has developed a variety of proprietary polymer manufacturing and formulation methods, including a method for physically encapsulating active pharmaceutical ingredients (“APIs”) inside polymer micelle nanoparticles that are transiently stable and disintegrate preferentially in the tumor microenvironment.

Intezyne’s most advanced product is IT-141, which directly delivers SN-38, the active moiety of Captosar(R) (irinotecan). Clinical trials conducted with IT-141 demonstrate that Intezyne’s technology can be successfully applied to improve delivery of a wide variety of oncology compounds.